METTL3–YTHDF1–driven m6A enhancement of MYC signaling orchestrates DNA repair and metabolic reprogramming to promote chemoresistance in colorectal cancer

METTL3-m6A-IGF2BP2 Axis-Mediated Stabilization of MTFR1 Promotes Glycolytic Reprogramming in Colorectal Cancer.

BACKGROUND Metabolic reprogramming fuels colorectal cancer (CRC), yet upstream regulators that lock cells into a glycolytic state remain incompletely defined. METHODS We integrated single-cell and spatial transcriptomics with GWAS-eQTL-Mendelian randomization to nominate CRC-associated candidate genes, and profiled t...

Targeting the METTL5–MGST1 axis for cancer therapy: molecular mechanisms and therapeutic implications

Epigenetically driven GAS2L3 enforces non-canonical cell cycle progression to promote osimertinib resistance in lung adenocarcinoma

These results uncover a metabolism-epigenetics–cell cycle interface that may represent a therapeutic vulnerability in EGFR-mutant LUAD and identify a glycolysis–H4K8la–GAS2L3 axis that drives noncanonical cell-cycle reprogramming independently of classical Cyclin–CDK activation, thereby promoting acquired osimertinib r...

MCM10, regulated by METTL3/ YTHDF1-mediated m6A modification, contributes to colorectal cancer progression through induction of M2 macrophage polarization

Colorectal cancer (CRC) remains a major contributor to cancer-related mortality worldwide. Although minichromosome maintenance protein 10 (MCM10) is known for its role in DNA replication, its involvement in CRC progression has not been fully elucidated. To identify key oncogenic drivers, RNA sequencing was performe...

The long non-coding RNA-encoded microprotein MKKS3 drives colorectal cancer chemoresistance.

Although oxaliplatin is widely used in the frontline treatment of colorectal cancer (CRC), CRC recurrence is commonly observed owing to oxaliplatin resistance. The roles of long non-coding RNAs-encoded microproteins in oxaliplatin chemoresistance remain inadequately explored. In this study, a CRISPR/Cas9 library was de...

Targeting MAT2A-S-adenosylmethionine (SAM) Axis Attenuates DNA Damage Response and Cancer Stemness to Increase Platinum Sensitivity in Ovarian Cancer

Metabolic and epigenetic reprogramming drives development of platinum resistance and disease recurrence in high-grade serous ovarian cancer (HGSC), a major clinical challenge in the field. S-adenosylmethionine (SAM) is the universal methyl group donor, synthesized by methionine adenosyltransferase 2A (MAT2A) from methi...